Chronic induction. What's new in the pipeline

Area of Science:

• Immunology
• Nephrology
• Pharmacology

Background:

• Biological agents for induction therapy, introduced in the 1970s, have seen little change in approach for decades.
• Current induction therapy relies on agents with significant toxic and nephrotoxic potential.
• The development of novel biological agents signifies a shift towards more targeted and potentially safer therapeutic strategies.

Purpose of the Study:

• To review the evolving landscape of biological agents for induction therapy in transplantation.
• To highlight novel agents designed for chronic therapy with objectives of reduced toxicity and improved outcomes.
• To discuss the potential impact of these new agents on current transplantation drug regimens.

Main Methods:

• Review of emerging biological agents for induction therapy.
• Identification of targets including CD11a, CD154, CD40, IL-15, and costimulatory molecules (CD80/CD86, CTLA4Ig).
• Analysis of the shift from short-term to chronic therapy designs.

Main Results:

• Several novel biological agents are under development, including efalizumab, anti-CD154, anti-CD40, IL-15 targeting agents, and costimulation blockers (e.g., LEA29Y).
• These agents are designed for chronic administration, aiming to reduce reliance on nephrotoxic drugs.
• The next decade is anticipated to see a new class of biological induction agents emerge.

Conclusions:

• Novel biological agents represent a significant advancement in transplantation induction therapy.
• These agents offer the potential to reduce toxicity, improve patient outcomes, and facilitate tolerance.
• A new generation of biological induction agents may supersede some existing oral drugs in renal transplantation within the next ten years.